Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | PAM | P19021 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313515 | 1.00 | ESR1 (0.54) | ESR1ESR2GRIA1FOLH1SLC7A5 | |
| SCHEMBL26778812 | 1.00 | ESR1 (0.54) | ESR1ESR2GRIA1FOLH1SLC7A5 | |
| SCHEMBL6518708 | 0.90 | ACE (0.55) | ESR1ESR2GRIA1FOLH1SLC7A5 | |
| SCHEMBL468899 | 0.90 | ACE (0.55) | ESR1ESR2GRIA1FOLH1SLC7A5 | |
| SCHEMBL18951703 | 0.88 | CTSS (0.59) | GRIA1CTSSCTSKPAMCPA1 | |
| Acetyl Tyrosine SCHEMBL8977600 | 0.88 | FOLH1 (0.66) | GRIA1FOLH1SLC7A5LMNANAALAD2 | |
| Acetyl Tyrosine SCHEMBL313539 | 0.88 | FOLH1 (0.66) | GRIA1FOLH1SLC7A5LMNANAALAD2 | |
| Acetyl Tyrosine SCHEMBL8977601 | 0.88 | FOLH1 (0.66) | GRIA1FOLH1SLC7A5LMNANAALAD2 | |
| Acetyl Tyrosine SCHEMBL1204300 | 0.88 | FOLH1 (0.66) | GRIA1FOLH1SLC7A5LMNANAALAD2 | |
| Acetyl Tyrosine SCHEMBL321220 | 0.88 | FOLH1 (0.66) | GRIA1FOLH1SLC7A5LMNANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197437-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161563-A1 | A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-07-12 | — | — | US | disclosed |
| US-7229966-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7186691-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157426-B2 | such as peptide YY, Neuropeptide Y, or Pancreatic polypeptide with solubilizing agent (cyclodextran), chelating agent (ethylenediamine tetraacetic acid), and polyol such as sucrose | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1715885-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-0842923-B1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU CO LTD (JP) | 2006-03-01 | — | — | EP | disclosed |
| US-7005141-B2 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1581245-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005080433-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004056314-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20030012817-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6461643-B2 | CONSISTS OF AT LEAST ONE BIOLOGICALLY- ACTIVE AGENT; (B) AT LEAST ONE CARRIER COMPRISING AN ACYLATED ALDEHYDE OF AN AMINO ACID, AN ACYLATED KETONE OF AN AMINO ACID, AN ACYLATED ALDEHYDE OF A PEPTIDE, AN ACYLATED KETONE OF A PEPTIDE | EMISPHERE TECHNOLOGIES, INC. | 2002-10-08 | — | — | US | disclosed |
| CN-1090617-C | Pyrrole derivatives and pharmaceutical compositions | NIPPON SHINYAKU CO LTD (JP) | 2002-09-11 | — | — | CN | disclosed |
| CN-1349796-A | Pyrrole derivatives and medicine composition | NIPPON SHINYAKU CO LTD (JP) | 2002-05-22 | — | — | CN | disclosed |
| US-20020052422-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6172102-B1 | POLLAKIURIA OR URINARY INCONTINENCE | NIPPON SHINYAKU CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-5998459-A | INCOTINENCE THERAPY | NIPPON SHINYAKU CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| CN-1186485-A | Pyrrole derivatives and pharmaceutical compositions | NIPPON SHINYAKU CO LTD (JP) | 1998-07-01 | — | — | CN | disclosed |
| EP-0842923-A1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012817-A1 | Oral drug delivery compositions and methods | PTMS, ADM2, DNPEP | ESR1 2554/4885ESR2 2941/4885GRIA1 2518/4885 |
| US-20020052422-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | ESR1 2716/4885ESR2 2729/4885GRIA1 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.